Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Malahayati International Journal of Nursing and Health Science
Sanad, Sakinah Mar'ie
Unknown Affiliation
Health Professions Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
HER2 positivity as a predictor of brain metastases in breast cancer: A systematic literature review Sanad, Sakinah Mar'ie; Adnyana, I Made Oka; Widyadharma, I Putu Eka
Malahayati International Journal of Nursing and Health Science Vol. 8 No. 8 (2025): Volume 8 Number 8
Publisher : Program Studi Ilmu Keperawatan-fakultas Ilmu Kesehatan Universitas Malahayati

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33024/minh.v8i8.1159

Abstract

Background: Breast cancer remains one of the most prevalent and lethal malignancies among women globally, which leads to the critical importance of early detection and a more comprehensive approach to breast cancer management. Purpose: To investigate HER2 positivity as a predictor of brain metastases in breast cancer. Methods: A total of 23 peer-reviewed studies published between 2015 and 2025 were analyzed, including randomized trials, retrospective cohorts, prediction model studies, and registry-based evaluations. Eligibility was guided by the PICOTS framework, and databases searched included PubMed, Scopus, MDPI, Elsevier, SagePub, and BMC Cancer. Results: The review confirms that HER2 overexpression significantly correlates with earlier brain metastasis onset, increased incidence, and distinctive treatment response profiles. HER2 status also influences survival outcomes and benefits from targeted agents such as trastuzumab, tucatinib, and pyrotinib. HER2-low expression additionally showed intermediate risk profiles, while imaging and circulating tumor cell data added prognostic value. Conclusion: HER2 positivity is a robust, independent predictor of brain metastasis in breast cancer patients. Routine integration of HER2 profiling in CNS risk assessment models may improve early detection and therapeutic precision, ultimately enhancing clinical outcomes for high-risk populations.
Co-Authors I Made Oka Adnyana I Putu Eka Widyadharma